Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1987 1
1992 1
1997 1
2000 1
2002 1
2004 2
2005 1
2007 3
2009 1
2010 2
2011 4
2012 2
2013 2
2014 5
2015 1
2016 2
2017 5
2018 3
2019 1
2020 3
2021 4
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review.
Green PHR, Paski S, Ko CW, Rubio-Tapia A. Green PHR, et al. Gastroenterology. 2022 Nov;163(5):1461-1469. doi: 10.1053/j.gastro.2022.07.086. Epub 2022 Sep 19. Gastroenterology. 2022. PMID: 36137844 Review.
It will review evaluation of patients with celiac disease who have persistent or recurrent symptoms, differential diagnosis, nutritional support, potential therapeutic options, and surveillance for complications of this condition. ...If villous atrophy persists or the init …
It will review evaluation of patients with celiac disease who have persistent or recurrent symptoms, differential diagnosis, nutritional sup …
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees.
Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, Engel E, Walter JE, Truong TQ, Khan DA, Ballow M, Cunningham-Rundles C, Lu H, Kwan M, Barmettler S. Otani IM, et al. J Allergy Clin Immunol. 2022 May;149(5):1525-1560. doi: 10.1016/j.jaci.2022.01.025. Epub 2022 Feb 14. J Allergy Clin Immunol. 2022. PMID: 35176351 Free article.
When iatrogenic causes cannot be removed or underlying conditions cannot be reversed, therapeutic options are not clearly delineated but include heightened monitoring for clinical infections, supportive antimicrobials, and in some cases, immunoglobulin replacement thera …
When iatrogenic causes cannot be removed or underlying conditions cannot be reversed, therapeutic options are not clearly delineated …
British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.
Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, Longhurst HJ, Patel SY, Renzoni EA, Sander CR, Avery GR, Babar JL, Buckland MS, Burns S, Egner W, Gompels MM, Gordins P, Haddock JA, Hart SP, Hayman GR, Herriot R, Hoyles RK, Huissoon AP, Jacob J, Nicholson AG, Rassl DM, Sargur RB, Savic S, Seneviratne SL, Sheaff M, Vaitla PM, Walters GI, Whitehouse JL, Wright PA, Condliffe AM. Hurst JR, et al. J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):938-945. doi: 10.1016/j.jaip.2017.01.021. Epub 2017 Mar 25. J Allergy Clin Immunol Pract. 2017. PMID: 28351785 Free article. Review.
A proportion of people living with common variable immunodeficiency disorders develop granulomatous-lymphocytic interstitial lung disease (GLILD). ...There was 100% agreement (score, 0.92 0.19) for the following definition: "GLILD is a distinct clinico-radio- …
A proportion of people living with common variable immunodeficiency disorders develop granulomatous-lymphocytic interst …
Phenotype, genotype, treatment, and survival outcomes in patients with X-linked inhibitor of apoptosis deficiency.
Yang L, Booth C, Speckmann C, Seidel MG, Worth AJJ, Kindle G, Lankester AC, Grimbacher B; ESID Clinical and Registry Working Parties; Gennery AR, Seppanen MRJ, Morris EC, Burns SO. Yang L, et al. J Allergy Clin Immunol. 2022 Aug;150(2):456-466. doi: 10.1016/j.jaci.2021.10.037. Epub 2021 Dec 15. J Allergy Clin Immunol. 2022. PMID: 34920033
For conservatively managed patients reaching adulthood, survival probabilities were 86% at age 30 years and 37% by age 52 years, with worse outcomes for patients developing the disease before the age of 5 years or with new disease features in adulthood. Nine asymptomatic m …
For conservatively managed patients reaching adulthood, survival probabilities were 86% at age 30 years and 37% by age 52 years, with worse …
Advances and highlights in primary immunodeficiencies in 2017.
Chinen J, Cowan MJ. Chinen J, et al. J Allergy Clin Immunol. 2018 Oct;142(4):1041-1051. doi: 10.1016/j.jaci.2018.08.016. Epub 2018 Aug 29. J Allergy Clin Immunol. 2018. PMID: 30170128 Free PMC article. Review.
This manuscript reviews selected topics in primary immunodeficiency diseases (PIDDs) published in 2017. These include (1) the role of follicular T cells in the differentiation of B cells and development of optimal antibody responses; (2) impaired nuclear factor kappaB subu …
This manuscript reviews selected topics in primary immunodeficiency diseases (PIDDs) published in 2017. These include (1) the role of …
Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Maarschalk-Ellerbroek LJ, et al. Int J Antimicrob Agents. 2011 May;37(5):396-404. doi: 10.1016/j.ijantimicag.2010.11.027. Epub 2011 Jan 26. Int J Antimicrob Agents. 2011. PMID: 21276714 Review.
The primary antibody deficiency syndromes are characterised by recurrent respiratory tract infections and the inability to produce effective immunoglobulin (Ig) responses. The best-known primary antibody deficiencies are common variable immunodeficiency (CVID …
The primary antibody deficiency syndromes are characterised by recurrent respiratory tract infections and the inability to produce effective …
A Novel Point-of-Care Rapid Diagnostic Test for Screening Individuals for Antibody Deficiencies.
Israeli S, Golden A, Atalig M, Mekki N, Rais A, Storey H, Barbouche MR, Peck R. Israeli S, et al. J Clin Immunol. 2022 Feb;42(2):394-403. doi: 10.1007/s10875-021-01179-0. Epub 2021 Nov 27. J Clin Immunol. 2022. PMID: 34839430 Free PMC article.
METHODS: Three prototype tests distinguishing low and normal IgG levels were evaluated with a blinded panel of serum/plasma specimens from 32 healthy controls and 86 primary immunodeficiency-confirmed patients with agammaglobulinemia, common variable immun …
METHODS: Three prototype tests distinguishing low and normal IgG levels were evaluated with a blinded panel of serum/plasma specimens from 3 …
Protein-losing Enteropathy as a Complication and/or Differential Diagnosis of Common Variable Immunodeficiency.
Sanges S, Germain N, Vignes S, Séguy D, Stabler S, Etienne N, Terriou L, Launay D, Hachulla É, Huglo D, Dubucquoi S, Labalette M, Lefèvre G. Sanges S, et al. J Clin Immunol. 2022 Oct;42(7):1461-1472. doi: 10.1007/s10875-022-01299-1. Epub 2022 Jun 23. J Clin Immunol. 2022. PMID: 35737255
As protein-losing enteropathy (PLE) can lead to hypogammaglobulinemia and lymphopenia, and since common variable immunodeficiency (CVID) is associated with digestive complications, we wondered if (1) PLE could occur during CVID and (2) specific features could …
As protein-losing enteropathy (PLE) can lead to hypogammaglobulinemia and lymphopenia, and since common variable immunodefi …
Clinical Features, Immunological Characteristics, and Treatment Outcomes of Campylobacter spp. Infections in Patients With Common Variable Immunodeficiency.
Roa-Bautista A, Brown LK, Tadros S, Burns SO, Godbole G, Lowe DM. Roa-Bautista A, et al. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3493-3501.e4. doi: 10.1016/j.jaip.2023.06.050. Epub 2023 Jul 3. J Allergy Clin Immunol Pract. 2023. PMID: 37406804 Free article.
BACKGROUND: Campylobacter infection usually causes a self-limited clinical illness lasting 5 to 7 days, resolving without antimicrobial treatment in immunocompetent subjects. However, an inadequate immune response can lead to a prolonged and severe disease requiring antibi …
BACKGROUND: Campylobacter infection usually causes a self-limited clinical illness lasting 5 to 7 days, resolving without antimicrobi …
Clinical picture and treatment of 2212 patients with common variable immunodeficiency.
Gathmann B, Mahlaoui N; CEREDIH; Gérard L, Oksenhendler E, Warnatz K, Schulze I, Kindle G, Kuijpers TW; Dutch WID; van Beem RT, Guzman D, Workman S, Soler-Palacín P, De Gracia J, Witte T, Schmidt RE, Litzman J, Hlavackova E, Thon V, Borte M, Borte S, Kumararatne D, Feighery C, Longhurst H, Helbert M, Szaflarska A, Sediva A, Belohradsky BH, Jones A, Baumann U, Meyts I, Kutukculer N, Wågström P, Galal NM, Roesler J, Farmaki E, Zinovieva N, Ciznar P, Papadopoulou-Alataki E, Bienemann K, Velbri S, Panahloo Z, Grimbacher B; European Society for Immunodeficiencies Registry Working Party. Gathmann B, et al. J Allergy Clin Immunol. 2014 Jul;134(1):116-26. doi: 10.1016/j.jaci.2013.12.1077. Epub 2014 Feb 28. J Allergy Clin Immunol. 2014. PMID: 24582312
BACKGROUND: Common variable immunodeficiency (CVID) is an antibody deficiency with an equal sex distribution and a high variability in clinical presentation. ...CONCLUSION: Patients with CVID are being managed differently throughout Europe, affecting various …
BACKGROUND: Common variable immunodeficiency (CVID) is an antibody deficiency with an equal sex distribution and a high …
52 results